Utama › Kanser Endometrium › Maryland
Kajian klinikal Kanser Endometrium di Maryland
22 kajian untuk Kanser Endometrium sedang mencari peserta di lokasi di Maryland.
Bandar di Maryland
Teks kajian rasmi (Bahasa Inggeris)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- dan 1 lagi
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05564377Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Okt 2026 · NCT07198074Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 72 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01174121A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06172478A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Sinai Hospital, Baltimore
- William Kahlert Reg. Can. Ctr, Westminster
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 9 Sep 2026 · NCT07166094DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Baltimore
- Research Site, Silver Spring
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 3 Sep 2026 · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- National Institutes of Health, Bethesda
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 29 Jul 2026 · NCT07044336Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07327489Vaginal Cuff Brachytherapy Fractionation Study
- University of Maryland Medical Center (UMMC), Baltimore
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 22 Apr 2026 · NCT03785288Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1/2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06253494Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Mac 2026 · NCT03968406Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Brandywine
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 24 Dis 2025 · NCT06463028A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Nov 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- dan 1 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mac 2025 · NCT04196257Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Silver Spring
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Wanita · Dikemas kini 2 Mei 2024 · NCT05797831Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.